Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT06202040
Other study ID # MacPower
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date December 22, 2023
Est. completion date January 25, 2024

Study information

Verified date May 2024
Source Konya City Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The respiratory system receives mechanical power (MP) throughout time during mechanical ventilation. Despite its life-saving benefits, mechanical ventilation can cause ventilator-induced lung injury (VILI). Recently, VILI has been linked to mechanical power, or the amount of energy the mechanical ventilator sends to the respiratory system in a given time. The hunt for lung damage-reducing characteristics, notably after VILI and ARDS (Acute respiratory distress syndrome), has increased after Covid-19. Mechanical power must be used more to promote lung protection. We examined the effects of bilateral rectus sheath and OSTAP (Oblique Subcostal Transversus Abdominis Plane ) block on mechanically powered patients.


Description:

MP is the energy transmitted over time to the respiratory system during mechanical ventilation. Although mechanical ventilation is a life-supporting treatment, it has the potential to cause damage to the lung structure in a process referred to as VILI. Recently, the degree of VILI has been associated with the amount of energy transmitted to the respiratory system by the mechanical ventilator within a specific time frame, which is referred to as mechanical power. After the occurrence of Covid-19, the search for parameters to reduce lung damage, especially following VILI and ARDS, has become more prominent. In this regard, promoting lung protection requires the more widespread use of mechanical power. We aimed to investigate the effect of bilateral rectus sheath and OSTAP block applied to patients on mechanical power.


Recruitment information / eligibility

Status Completed
Enrollment 66
Est. completion date January 25, 2024
Est. primary completion date January 15, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: - Patients aged between 18 and 65 years - ASA 1-2 patients - Patients undergoing elective laparoscopic cholecystectomy Exclusion Criteria: - Mental retardation, - Severe presence of COPD, - Uncontrolled Bronchial Asthma, - Decompensated Heart Failure (NYHA 3-4), - History of previous lung surgery, - Patients unwilling to participate in the study, - Local anesthetic allergy, - History of chronic pain and treatment, - Morbid obesity (body mass index (BMI) >35), - Pregnancy, - Patients converted to open cholecystectomy

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Bilateral Oblique Subcostal Transversus Abdominis Plane Block (OSTAP) will be performed.
The OSTAP block will be conducted in-plane using a 100mm 22 G needle and a linear probe under ultrasound (USG) guidance. The 20cc block will contain 10cc of 0.5% bupivacaine and 10cc of normal saline. Bilateral OSTAP will be administered with 20cc (10cc per side). To apply the block, position the linear probe parallel to the rib edge immediately below it on the anterior abdominal wall. Visible will be the external, internal, transversus abdominis, and rectus muscle junction. The needle tip will move toward the TAP space (between the internal oblique and transversus abdominis muscles). To ensure medication delivery, the needle tip will be visible in the TAP and the drug will be aspirated negatively. USG will also observe drug distribution at the rectus abdominis muscle-TAP space junction.
Bilateral Rectus Sheath Block (RSB) will be performed.
When the patient is in the supine position, the ultrasound (USG) linear probe is held in the transverse plane at the level just above the umbilicus, where the posterior rectus sheath is best visualized. Using the in-plane technique with a 100mm 22 G needle under USG guidance, the drug prepared will be administered between the rectus muscle and the posterior rectus sheath. For this block, a volume of 20cc will be prepared, consisting of 10cc of 0.5% bupivacaine and 10cc of normal saline. Bilateral Rectus Sheath Block (RSB) will be applied with a total volume of 20cc, 10cc to each side.

Locations

Country Name City State
Turkey Konya City Hospital Konya

Sponsors (1)

Lead Sponsor Collaborator
Konya City Hospital

Country where clinical trial is conducted

Turkey, 

Outcome

Type Measure Description Time frame Safety issue
Primary mechanical power will be calculated from these measurements (mec power 1, mec power 2, mec power 3) as a joule. Primary outcome measures will be based on intraoperative measurements taken from the mechanical ventilator, and mechanical power will be calculated from these measurements (mec power 1, mec power 2, mec power 3). Comen after intubation (before the block procedure), end of the surgery pre sugammadex administration and end of the surgery post sugammadex administration
Secondary Visual Analog Scale (VAS) for pain evaluation (0-10, 0 = no pain, 10 = the most severe pain). Secondary outcome measures will include postoperative assessments at 30 minutes, 2 hours, 8 hours, and 24 hours, using the Visual Analog Scale (VAS) for pain evaluation (0-10, 0 = no pain, 10 = the most severe pain). postoperative assessments at 30 minutes, 2 hours, 8 hours, and 24 hours
Secondary the Quality of Recovery-15 Test (QoR-15T) [ Excellent (QoR-15 > 135 point), Good (122 = QoR-15 = 135 points), Moderate (90 = QoR-15 = 121 point), Poor (QoR-15 < 90 points) ] Secondary outcome measures will include postoperative assessments at 24 hours, the Quality of Recovery-15 Test (QoR-15T) will be used to assess patient recovery quality. Postoperative assessments at 24 hours
Secondary Number of rescue analgesic needs Secondary outcome measures will include postoperative assessments at 30 minutes, 2 hours, 8 hours, and 24 hours, number of rescue analgesic needs will be recorded. Postoperative assessments at 30 minutes, 2 hours, 8 hours, and 24 hours
See also
  Status Clinical Trial Phase
Completed NCT04193254 - LPP , MP and DP:Relation With Mortality and SOFA in Mechanically Ventilated Patients in ER, Ward and ICU
Recruiting NCT06062212 - Effect of Transpulmonary MP on Prognosis of Patients With Severe ARDS Treated With VV-ECMO
Recruiting NCT05559970 - Inhalational Sedation and Mechanical Power N/A
Recruiting NCT03939260 - ECCO2R - Mechanical Power Study
Recruiting NCT06400095 - Ventilatory Parameters in Predicting Outcomes in ARDS Patients
Completed NCT04827927 - The Effect of Closed-Loop Versus Conventional Ventilation on Mechanical Power N/A
Recruiting NCT03616704 - Effects of Different Driving Pressure on Lung Stress, Strain and Mechanical Power in Patients With Moderate to Severe ARDS
Completed NCT05962125 - The Role of Periodic Alveolar Recruitment Maneuvers in Intraoperative Protective Ventilation N/A
Recruiting NCT06462976 - Postoperative Pulmonary Complications in Adult PNL Patients
Recruiting NCT06425354 - Use of 'Mechanical Power' as a Predictor of Increased Serum and Pulmonary Proinflammatory Cytokine Concentrations in Patients With Acute Hypoxemic Respiratory Failure: A Prospective Observational Study